Li Xuewei, Zhang Wenhui, Li Saisai, Ma Xiaolin, Shi Xue, Wang Wei, Sun Lingjie, Qiu Kuan, Zhao Yanxia, Zhao Chunting, Liu Xiaodan
Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
Department of Bone Marrow Transplantation, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
Front Immunol. 2025 Jul 9;16:1607926. doi: 10.3389/fimmu.2025.1607926. eCollection 2025.
Hematopoietic stem cell transplantation (HSCT) offers a potentially curative option for severe aplastic anemia (SAA). However, graft failure (GF) remains a life-threatening complication following HSCT. Haploidentical HSCT may serve as an effective salvage therapy for the treatment of GF.
This report describes a 3-year-old girl with acquired SAA who experienced GF twice following matched unrelated donor (MUD) transplantations. Successful engraftment was ultimately achieved through a third haploidentical donor HSCT. This work was conducted in accordance with the Declaration of Helsinki and the Declaration of Istanbul.
Based on our experience with this case, we conclude that a third HSCT with a haploidentical donor represents a viable approach to extending survival.
造血干细胞移植（HSCT）为重型再生障碍性贫血（SAA）提供了一种潜在的治愈选择。然而，移植失败（GF）仍然是HSCT后一种危及生命的并发症。单倍体相合HSCT可作为治疗GF的一种有效挽救疗法。
本报告描述了一名3岁获得性SAA女童，在接受匹配无关供体（MUD）移植后发生了两次GF。最终通过第三次单倍体相合供体HSCT成功实现了植入。本研究是根据《赫尔辛基宣言》和《伊斯坦布尔宣言》进行的。
基于我们对该病例的经验，我们得出结论，第三次单倍体相合供体HSCT是延长生存期的一种可行方法。
